Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/7 cls
Adolor (ADLR) Pacific Growth Gregory Wade Upgrade Buy (from neutral) 30% $5.07
Wade upgraded the stock after the company partnered with Pfizer (PFE) to develop and commercialize ADLR's ADL5859 and ADL5747 for pain (see B2). He noted that more than half of the $232.5M in milestones can be earned prior to regulatory approval.
Allos (ALTH) Banc of America Securities Katherine Kim New Buy 3% $7.12
Kim set an $11 target. In late 2008, she expects data from the pivotal Phase II PROPEL trial of Pralatrexate (PDX) to treat peripheral T cell lymphoma (PTCL).
ArQule (ARQL) Banc of America Securities Katherine Kim New

Read the full 1198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE